Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis.
BACKGROUND
Aberrant expression of microRNAs is associated with neointimal hyperplasia (NIH) in type 2 diabetes. We prospectively compared the effects of pioglitazone on coronary NIH and changes in microRNAs according to NIH status in type 2 diabetic patients during 9-month follow-up.


RESULTS
Type 2 diabetic patients were randomly assigned to the pioglitazone (n=36) or control groups (n=36) after coronary stenting. Primary endpoint was the comparison of changes in neointimal volume on OCT and in the level of circulating microRNA-17,-24,-92a,-126 and -145 during 9-month follow-up. Secondary endpoint was the comparison of changes in brachial artery flow-mediated dilation and inflammatory markers such as IL-6, TNF-α, hsCRP, adiponectin, sICAM-1, and sVCAM-1 between the 2 groups. Neointimal volume was significantly lower in the pioglitazone group (25.02±17.78 mm(3)vs. 55.10±30.01 mm(3), P<0.001) with significant increases in circulating microRNA-24 (0.264±0.084 vs. 0.006±0.030, P<0.001) during follow-up. FMD was significantly greater in the pioglitazone than control group at 9 months (0.47±0.14 mm vs. 0.28±0.18 mm, P<0.05, respectively). Decreases in inflammatory markers such as IL-6, TNF-α, and sVCAM-1 were significantly greater in the pioglitazone than the control group during the follow-up.


CONCLUSIONS
Pioglitazone significantly decreased NIH with increases in circulating microRNA-24 at 9-month follow-up. The decrease in microRNA-24 could be used as a potential predictor of increases in NIH in type 2 diabetic patients.
Department of Cardiology, Cardiovascular Center, Korea University Anam Hospital.
Soon Jun
SJ
Hong
Seung Cheol
SC
Choi
Jae Young
JY
Cho
Hyung Joon
HJ
Joo
Jae Hyoung
JH
Park
Cheol Woong
CW
Yu
Do-Sun
DS
Lim
D000368:Aged; D003331:Coronary Vessels / Q000378:metabolism / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D003925:Diabetic Angiopathies / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D006965:Hyperplasia / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D058426:Neointima / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*; D041623:Tomography, Optical Coherence
D007004:Hypoglycemic Agents; C543845:MIRN24 microRNA, human; D035683:MicroRNAs; D045162:Thiazolidinediones; D000077205:Pioglitazone